A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. (Q45795602)
Jump to navigation
Jump to search
scientific article published on 5 June 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. |
scientific article published on 5 June 2013 |
Statements
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors (English)
Balaji Venugopal
Rebecca S Kristeleit
Ruth Plummer
Adam Stewart
Nele Fourneau
Peter Hellemans
Yusri Elsayed
Steve McClue
Johan W Smit
Ann Forslund
Charles Phelps
John Camm
T R Jeffry Evans
Johann S de Bono